Literature DB >> 2178597

Inhibition of blood-aqueous humor barrier breakdown with diclofenac. A fluorophotometric study.

M C Kraff1, D R Sanders, L McGuigan, M G Raanan.   

Abstract

Various doses of a new topical nonsteroidal anti-inflammatory agent, diclofenac sodium, were tested against prednisolone sodium phosphate in a randomized double-masked study to determine comparative efficacy and safety regarding the reduction of postsurgical ocular inflammation. Inflammation was assessed by measuring fluorescein leakage into the anterior chamber using fluorophotometry techniques. Increased leakage in each patient's operated-on eye compared with the unoperated-on control eye was attributed to a breakdown in the blood-aqueous barrier caused by the cataract surgery. Elimination or significant reduction of fluorescein leakage within a treatment group constituted increased efficacy in controlling inflammation. A total of 124 cases were analyzed. There were no preoperative differences among groups in fluorescein leakage. At 1 week after surgery, all three diclofenac groups had significantly less fluorescein leakage compared with the prednisolone group. Mean percent increases were 56% to 118% in diclofenac groups vs 324% in the prednisolone group. No differences among diclofenac concentrations were detected. The differences between prednisolone and diclofenac were also present, although of lesser magnitude, at 3 weeks. This demonstration of increased efficacy of the nonsteroidal anti-inflammatory agent vs prednisolone is promising given the known side effects of ocular steroids.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178597     DOI: 10.1001/archopht.1990.01070050078035

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  10 in total

1.  In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note.

Authors:  Manjusha Malhotra; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2005-10-24       Impact factor: 3.246

2.  Diffusion coefficient through the blood-aqueous barrier using a standard protocol.

Authors:  J van Best; J B del Castillo; M Diestelhorst; B Heintz; E Leite; L F Liesenborghs; R Schalnus
Journal:  Br J Ophthalmol       Date:  1996-04       Impact factor: 4.638

Review 3.  The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology.

Authors:  P Koay
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

4.  Comparison of the efficacy of diclofenac and betamethasone following strabismus surgery.

Authors:  M Wright; Z Butt; G McIlwaine; B Fleck
Journal:  Br J Ophthalmol       Date:  1997-04       Impact factor: 4.638

5.  Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery.

Authors:  C-G Laurell; C Zetterström
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

Review 6.  Ocular diclofenac. A review of its pharmacology and clinical use in cataract surgery, and potential in other inflammatory ocular conditions.

Authors:  K L Goa; P Chrisp
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

Review 7.  Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery.

Authors:  Viral V Juthani; Elizabeth Clearfield; Roy S Chuck
Journal:  Cochrane Database Syst Rev       Date:  2017-07-03

Review 8.  The role of NSAIDs in the management of postoperative ophthalmic inflammation.

Authors:  Joseph Colin
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes.

Authors:  Seok Hyeon Song; Seung Kook Baek; Min Woo Lee; Young Hoon Lee
Journal:  Korean J Ophthalmol       Date:  2020-02

10.  Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification.

Authors:  Narayan Bardoloi; Sandip Sarkar; Pankaj Suresh Burgute; Amit Kumar Deb; Roshni Dholkawala; Priyal Aggarwal; Tanmay Gokhale
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.